In the Japanese pharmaceutical industry, there were 19 M&A deals announced in Q4 2023, worth a total value of $1.5bn, according to GlobalData’s Deals Database. The $1.4bn majority acquisition of NICHII HOLDINGS by Nippon Life Insurance was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Japan increased by 201% in Q4 2023 compared with the previous quarter’s total of $498.7m and rose by 4529% as compared to Q4 2022. Related deal volume increased by 12% in Q4 2023 versus the previous quarter and was 5% lower than in Q4 2022.
The top-ranked financial advisors supporting these M&A deals in Japan in Q4 2023 were Aizawa Securities; Centerview Partners; Daiwa Securities Group with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in Japan Q4 2023 were Baker & McKenzie; Cravath, Swaine & Moore; Nishimura & Asahi with 1, 1, 1 deals respectively.
See Also:
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.